Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

8.2

 

EUR

 

-4.65 %

Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

5,297 following
Compare
-4.65%
+62.06%
+121.62%
+176.09%
+178.91%
+233.33%
+82.63%
+250.98%
-98.65%

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
58.73M EUR
Turnover
221.47K EUR
P/E (adj.) (24e)
-606.37
EV/EBIT (adj.) (24e)
18,722.76
P/B (24e)
15.57
EV/S (24e)
6.47
Dividend yield-% (24e)
-
Coverage
Recommendation
Accumulate
Target price
6.20 EUR
Updated
2024-12-02
Disclaimer
Latest research

Latest analysis report

Released: 2024-12-02

Latest extensive report

Released: 2023-10-06

Financial calendar
27/2
2025

Annual report '24

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Research by
Antti Siltanen

Nexstim: Further evidence of cash flow turnaround

Nexstim's year of surprises continued on Friday when the company announced a new development and distribution cooperation agreement with Germany's Brainlab AG. The agreement will strengthen Nexstim's financial position and improve its performance starting next year.

Nexstim
Business news update from Nexstim
Analyst Comment by
Antti Siltanen

Business news update from Nexstim

Nexstim issued a press release on business highlights for January-September. The company said it has invested in profitable growth, development of its NBS 6 diagnostics product and expansion of its network of clinics.

Nexstim
Forum discussions
Nu analys på Nexstim utgavs i dag Nexstim: New year starts in a mixed atmosphere - Inderes
1/3/2024, 1:22 PM
by Pia Maljanen
2
Sara, @antti.siltanen ja Nexstim Content: 00:00 Introduction 00:15 Nexstim as a company 02:25 Business model 04:50 Market and competition 07:07 Value drivers and risk factors 09:17 Strategy 10:00 Financial position 11:11 Estimates and valuation Inderes — Connecting Investors and ...
10/9/2023, 11:38 AM
by börsen84
2
Här är en helt färsk analys av det här företaget. Inderes — Connecting Investors and Companies Nexstim: Growth initiatives waiting for lift-off Nexstim is a medical technology company whose transcranial magnetic stimulation systems are used in pre-operative brain mapping and to treat...
10/6/2023, 1:51 PM
by börsen84
2
Medicinteknikföretaget Nexstim publicerade sin delårsrapport för januari–september där de redogjorde för investeringar i lönsam tillväxt, utvecklingen av diagnostiksystemet NBS 6 samt utökningen av sitt kliniknätverk. Enligt företaget hade 11 nya system levererats och ytterligare...
10/31/2024, 11:28 AM
by börsen84
1
@antti.siltanen has done a good and high-quality analysis of this company. It’s worth reading! Inderes Nexstim: The end of the year laid a firmer foundation for the future - Inderes Revenue was slightly higher than the preliminary data suggested and the result hit our forecasts. ...
2/28/2024, 5:05 PM
by börsen84
1
Ägarna till Nexstim har en spännande dag på tisdag. Inderes Nexstim H2 on Tuesday: A record-breaking end to the year - Inderes The company issued a profit warning early in the year, saying that full-year EBITDA would be negative (guidance: Positive EBITDA). H2 revenue level of 4....
2/22/2024, 6:31 AM
by börsen84
1
Inderes Nexstim’s system sales progressed well in H2 - Inderes Nexstim’s H2 was positive in terms of announced system sales. During the reporting period, the company announced 16 system sales of which 11 occurred in Q4. The total number of deals will only be revealed in the H2 report...
1/13/2024, 11:31 PM
by börsen84
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.